text:
Blood–brain barrier
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Blood–brain barrier
Blood and CSF brain barriers
Details
System
Neuroimmune system
Identifiers
Acronym(s)
BBB
MeSH
D001812
Anatomical terminology
[edit on Wikidata]
The blood–brain barrier (BBB) is a highly selective semipermeable membrane barrier that separates the circulating blood from the brain and extracellular fluid in the central nervous system (CNS).[1] The blood–brain barrier is formed by brain endothelial cells and it allows the passage of water, some gases, and lipid-soluble molecules by passive diffusion, as well as the selective transport of molecules such as glucose and amino acids that are crucial to neural function. Furthermore, it prevents the entry of lipophilic potential neurotoxins by way of an active transport mechanism mediated by P-glycoprotein. Astrocytes have been claimed to be necessary to create the blood–brain barrier. A few regions in the brain, including the circumventricular organs, do not have a blood–brain barrier.
The blood–brain barrier occurs along all capillaries and consists of tight junctions around the capillaries that do not exist in normal circulation.[1] Endothelial cells restrict the diffusion of microscopic objects (e.g., bacteria) and large or hydrophilic molecules into the cerebrospinal fluid (CSF), while allowing the diffusion of hydrophobic molecules (O2, CO2, hormones) and likely also small polar molecules.[2] Cells of the barrier actively transport metabolic products such as glucose across the barrier with specific proteins.[3] This barrier also includes a thick basement membrane and astrocytic endfeet.[4]
Contents
[hide]
1 Structure
1.1 Development
2 Function
2.1 Circumventricular organs
2.2 Specialized permeable zones
3 Clinical significance
3.1 As a drug target
3.1.1 Nanoparticles
3.1.2 Peptides
4 Disease
4.1 Meningitis
4.2 Brain abscess
4.3 Epilepsy
4.4 Multiple sclerosis
4.5 Neuromyelitis optica
4.6 Late-stage neurological trypanosomiasis (sleeping sickness)
4.7 Progressive multifocal leukoencephalopathy (PML)
4.8 De Vivo disease
4.9 Alzheimer's disease
4.10 Cerebral edema
4.11 Prion and prion-like diseases
4.12 HIV encephalitis
4.13 Rabies
4.14 Systemic inflammation
5 History
6 See also
7 References
8 Further reading
9 External links
Structure[edit]
Part of a network of capillaries supplying brain cells
The astrocytes type 1 surrounding capillaries in the brain
A cortical microvessel stained for blood–brain barrier protein ZO-1
Sketch showing constitution of blood vessels inside the brain
This "barrier" results from the selectivity of the tight junctions between endothelial cells in CNS vessels, which restricts the passage of solutes.[1] At the interface between blood and the brain, endothelial cells are stitched together by these tight junctions, which are composed of smaller subunits, frequently biochemical dimers, that are transmembrane proteins such as occludin, claudins, junctional adhesion molecule (JAM), or ESAM, for example.[3] Each of these transmembrane proteins is anchored into the endothelial cells by another protein complex that includes ZO-1 and associated proteins.[3]
The blood–brain barrier is composed of high-density cells restricting passage of substances from the bloodstream much more than do the endothelial cells in capillaries elsewhere in the body.[5] Astrocyte cell projections called astrocytic feet (also known as "glia limitans") surround the endothelial cells of the BBB, providing biochemical support to those cells.[6] The BBB is distinct from the quite similar blood–cerebrospinal fluid barrier, which is a function of the choroidal cells of the choroid plexus, and from the blood–retinal barrier, which can be considered a part of the whole realm of such barriers.[7]
Several areas of the human brain are not on the brain side of the BBB. Some examples of this include the circumventricular organs, the roof of the third and fourth ventricles, capillaries in the pineal gland on the roof of the diencephalon and the pineal gland. The pineal gland secretes the hormone melatonin "directly into the systemic circulation",[8] thus melatonin is not affected by the blood–brain barrier.[9]
Development[edit]
Originally, experiments in the 1920s seemed to (wrongly) show that the blood–brain barrier (BBB) was still immature in newborns. This was due to an error in methodology (the osmotic pressure was too high and the delicate embryonal capillary vessels were partially damaged). It was later shown in experiments with a reduced volume of the injected liquids that the markers under investigation could not pass the BBB. It was reported that those natural substances such as albumin, α-1-fetoprotein or transferrin with elevated plasma concentration in the newborn could not be detected outside of cells in the brain. The transporter P-glycoprotein exists already in the embryonal endothelium.[10]
The measurement of brain uptake of acetamide, antipyrine, benzyl alcohol, butanol, caffeine, cytosine, phenytoin, ethanol, ethylene glycol, heroin, mannitol, methanol, phenobarbital, propylene glycol, thiourea, and urea in ether-anesthetized newborn vs. adult rabbits shows that newborn rabbit and adult rabbit brain endothelia are functionally similar with respect to lipid-mediated permeability.[11] These data confirmed that no differences in permeability could be detected between newborn and adult BBB capillaries. No difference in brain uptake of glucose, amino acids, organic acids, purines, nucleosides, or choline was observed between adult and newborn rabbits.[11] These experiments indicate that the newborn BBB has restrictive properties similar to that of the adult. In contrast to suggestions of an immature barrier in young animals, these studies indicate that a sophisticated, selective BBB is operative at birth.
Function[edit]
See also: Neuroimmune system
The blood–brain barrier acts effectively to protect the brain from circulating pathogens. Accordingly, blood-borne infections of the brain are rare.[1] Infections of the brain that do occur are often difficult to treat. Antibodies are too large to cross the blood–brain barrier, and only certain antibiotics are able to pass.[12] In some cases, a drug has to be administered directly into the cerebrospinal fluid (CSF) where it can enter the brain by crossing the blood–cerebrospinal fluid barrier.[13][14]
The blood-brain barrier may become leaky in select neurological diseases, such as amyotrophic lateral sclerosis, epilepsy, brain trauma and edema, and in systemic diseases, such as liver failure.[1] The blood–brain barrier becomes more permeable during inflammation,[1] allowing antibiotics and phagocytes to move across the BBB. However, this also allows bacteria and viruses to infiltrate the blood-brain barrier.[12][15] Examples of pathogens that can traverse the blood-brain barrier include toxoplasma gondii which causes toxoplasmosis, spirochetes like Borrelia (Lyme disease), Group B streptococci which causes meningitis in newborns,[16] and Treponema pallidum which causes syphilis. Some of these harmful bacteria gain access by releasing cytotoxins like pneumolysin[17] which have a direct toxic effect on brain microvascular endothelium[18] and tight junctions.
Circumventricular organs[edit]
Main article: Circumventricular organs
Circumventricular organs (CVOs) are individual structures located adjacent to the fourth ventricle or third ventricle in the brain, and are characterized by dense capillary beds with permeable endothelial cells unlike those of the blood-brain barrier.[19][20] Included among CVOs having highly permeable capillaries are the area postrema, subfornical organ, vascular organ of the lamina terminalis, median eminence, pineal gland, and three lobes of the pituitary gland.[19][21]
Permeable capillaries of the sensory CVOs (area postrema, subfornical organ, vascular organ of the lamina terminalis) enable rapid detection of circulating signals in systemic blood, while those of the secretory CVOs (median eminence, pineal gland, pituitary lobes) facilitate transport of brain-derived signals into the circulating blood.[19][20] Consequently, the CVO permeable capillaries are the point of bidirectional blood-brain communication for neuroendocrine function.[19][21][22]
Specialized permeable zones[edit]
The border zones between brain tissue "behind" the blood-brain barrier and zones "open" to blood signals in certain CVOs contain specialized hybrid capillaries that are leakier than typical brain capillaries, but not as permeable as CVO capillaries. Such zones exist at the border of the area postrema–nucleus tractus solitarii (NTS),[23] and median eminence–hypothalamic arcuate nucleus.[22][24] These zones appear to function as rapid transit regions for brain structures involved in diverse neural circuits – like the NTS and arcuate nucleus – to rapidly control neurohumoral integration.[22][23] The permeable capillary zone shared between the median eminence and hypothalamic arcuate nucleus is augmented by wide pericapillary spaces, facilitating bidirectional flow of solutes between the two structures, and indicating that the median eminence is not only a secretory organ, but may also be a sensory CVO.[22][24]
Clinical significance[edit]
As a drug target[edit]
Main article: Nanoparticles for drug delivery to the brain
The blood–brain barrier (BBB) is formed by the brain capillary endothelium and excludes from the brain ∼100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs.[1] Overcoming the difficulty of delivering therapeutic agents to specific regions of the brain presents a major challenge to treatment of most brain disorders. In its neuroprotective role, the blood–brain barrier functions to hinder the delivery of many potentially important diagnostic and therapeutic agents to the brain. Therapeutic molecules and antibodies that might otherwise be effective in diagnosis and therapy do not cross the BBB in adequate amounts.
Mechanisms for drug targeting in the brain involve going either "through" or "behind" the BBB. Modalities for drug delivery in unit doses through the BBB entail its disruption by osmotic means; biochemically by the use of vasoactive substances such as bradykinin;[25] or even by localized exposure to high-intensity focused ultrasound (HIFU).[26] Other methods used to get through the BBB may entail the use of endogenous transport systems, including carrier-mediated transporters such as glucose and amino acid carriers; receptor-mediated transcytosis for insulin or transferrin; and the blocking of active efflux transporters such as p-glycoprotein. However, vectors targeting BBB transporters, such as the transferrin receptor, have been found to remain entrapped in brain endothelial cells of capillaries, instead of being ferried across the BBB into the cerebral parenchyma.[27][28] Methods for drug delivery behind the BBB include intracerebral implantation (such as with needles) and convection-enhanced distribution. Mannitol can be used in bypassing the BBB.
Nanoparticles[edit]
Nanotechnology may also help in the transfer of drugs across the BBB.[29][30] Recently, researchers have been trying to build liposomes loaded with nanoparticles to gain access through the BBB. More research is needed to determine which strategies will be most effective and how they can be improved for patients with brain tumors. The potential for using BBB opening to target specific agents to brain tumors has just begun to be explored.
Delivering drugs across the blood–brain barrier is one of the most promising applications of nanotechnology in clinical neuroscience. Nanoparticles could potentially carry out multiple tasks in a predefined sequence, which is very important in the delivery of drugs across the blood–brain barrier.
A significant amount of research in this area has been spent exploring methods of nanoparticle-mediated delivery of antineoplastic drugs to tumors in the central nervous system. For example, radiolabeled polyethylene glycol coated hexadecylcyanoacrylate nanospheres targeted and accumulated in a rat gliosarcoma.[31] However, this method is not yet ready for clinical trials, due to the accumulation of the nanospheres in surrounding healthy tissue. Another, more promising approach, is the coating of polyalkylcyanoacrylate or poly-lactic-co-glycolic acid (PLGA) nanoparticles with polysorbate 80 or poloxamer 188. Due to this coating the particles adsorb apolipoproteins E or A-1 from the blood and thus interact with the LRP1 or with the scavenger receptor followed by transcytosis across the blood-brain barrier into the brain.[32] These particles loaded with doxorubicin for the treatment of glioblastomas are presently in Clinical Phase I. Recently, a novel class of multifunctional nanoparticles known as magneto-electric nanoparticles (MENs) has been discovered for externally controlled targeted delivery and release of drug(s) across BBB as well as wireless stimulation of cells deep in the brain. This approach depends more on the field control and less on the cellular microenvironment. In vitro and in vivo (on mice) experiments to prove the feasibility of using MENs to release a drug across BBB on demand and wirelessly stimulate the brain have been conducted by the research group of Prof. Sakhrat Khizroev at Florida International University (FIU).[33]
Vascular endothelial cells and associated pericytes are often abnormal in tumors and the blood–brain barrier may not always be intact in brain tumors. Also, the basement membrane is sometimes incomplete. Other factors, such as astrocytes, may contribute to the resistance of brain tumors to therapy.[34][35]
Peptides[edit]
Peptides are able to cross the blood–brain barrier (BBB) through various mechanisms, opening new diagnostic and therapeutic avenues.[36] However, their BBB transport data are scattered in the literature over different disciplines, using different methodologies reporting different influx or efflux aspects. Therefore, a comprehensive BBB peptide database (Brainpeps) was constructed to collect the BBB data available in the literature. Brainpeps currently contains BBB transport information with positive as well as negative results. The database is a useful tool to prioritize peptide choices for evaluating different BBB responses or studying quantitative structure-property (BBB behaviour) relationships of peptides. Because a multitude of methods have been used to assess the BBB behaviour of compounds, we classified these methods and their responses. Moreover, the relationships between the different BBB transport methods have been clarified and visualized.[37]
Casomorphin is a heptapeptide and could be able to pass the BBB.[38]
Disease[edit]
Meningitis[edit]
Meningitis is an inflammation of the membranes that surround the brain and spinal cord (these membranes are known as meninges). Meningitis is most commonly caused by infections with various pathogens, examples of which are Streptococcus pneumoniae and Haemophilus influenzae. When the meninges are inflamed, the blood–brain barrier may be disrupted.[12] This disruption may increase the penetration of various substances (including either toxins or antibiotics) into the brain. Antibiotics used to treat meningitis may aggravate the inflammatory response of the central nervous system by releasing neurotoxins from the cell walls of bacteria - like lipopolysaccharide (LPS).[39] Depending on the causative pathogen, whether it is bacterial, fungal, or protozoan, treatment with third-generation or fourth-generation cephalosporin or amphotericin B is usually prescribed.[40]
Brain abscess[edit]
A brain or cerebral abscess, like other abscesses, is caused by inflammation and collection of lymphatic cells and infected material originating from a local or remote infection. A brain abscess is a rare, life-threatening condition. Local sources may include infections of the ear, the oral cavity and teeth, the paranasal sinuses, or an epidural abscess. Remote sources may include infections in the lung, heart or kidney. A brain abscess may also be caused by head trauma or as a complication of surgery. In children cerebral abscesses are usually linked to congenital heart disease.[41] In most cases, 8–12 weeks of antibacterial therapy is required.[12]
Epilepsy[edit]
Epilepsy is a common neurological disease that is characterized by recurrent and sometimes untreatable seizures. Several clinical and experimental data have implicated the failure of blood–brain barrier function in triggering chronic or acute seizures.[42][43][44][45][46] Some studies implicate the interactions between a common blood protein (albumin) and astrocytes.[47] These findings suggest that acute seizures are a predictable consequence of disruption of the BBB by either artificial or inflammatory mechanisms. In addition, expression of drug resistance molecules and transporters at the BBB are a significant mechanism of resistance to commonly used anti-epileptic drugs.[48][49]
Multiple sclerosis[edit]
Multiple sclerosis (MS) is considered to be an auto-immune and neurodegenerative disorder in which the immune system attacks the myelin that protects and electrically insulates the neurons of the central and peripheral nervous systems. Normally, a person's nervous system would be inaccessible to the white blood cells due to the blood–brain barrier. However, magnetic resonance imaging has shown that when a person is undergoing an MS "attack," the blood–brain barrier has broken down in a section of the brain or spinal cord, allowing white blood cells called T lymphocytes to cross over and attack the myelin. It has sometimes been suggested that, rather than being a disease of the immune system, MS is a disease of the blood–brain barrier.[50] The weakening of the blood–brain barrier may be a result of a disturbance in the endothelial cells on the inside of the blood vessel, due to which the production of the protein P-glycoprotein is not working well.[51]
There are currently active investigations into treatments for a compromised blood–brain barrier. It is believed that oxidative stress plays an important role into the breakdown of the barrier. Anti-oxidants such as lipoic acid may be able to stabilize a weakening blood–brain barrier.[52]
Neuromyelitis optica[edit]
Neuromyelitis optica, also known as Devic's disease, is similar to and is often confused with multiple sclerosis. Among other differences from MS, a different target of the autoimmune response has been identified. Patients with neuromyelitis optica have high levels of antibodies against a protein called aquaporin 4 (a component of the astrocytic foot processes in the blood–brain barrier).[53]
Late-stage neurological trypanosomiasis (sleeping sickness)[edit]
Late-stage neurological trypanosomiasis, or sleeping sickness, is a condition in which trypanosoma protozoa are found in brain tissue. It is not yet known how the parasites infect the brain from the blood, but it is suspected that they cross through the choroid plexus, a circumventricular organ.
Progressive multifocal leukoencephalopathy (PML)[edit]
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system that is caused by reactivation of a latent papovavirus (the JC polyomavirus) infection, that can cross the BBB. It affects immune-compromised patients and it is usually seen with patients suffering from AIDS.
De Vivo disease[edit]
De Vivo disease (also known as GLUT1 deficiency syndrome) is a rare condition caused by inadequate transportation of the sugar glucose across the blood–brain barrier, resulting in developmental delays and other neurological problems. Genetic defects in glucose transporter type 1 (GLUT1) appears to be the primary cause of De Vivo disease.[54][55]
Alzheimer's disease[edit]
Some evidence indicates that disruption of the blood–brain barrier in Alzheimer's disease patients allows blood plasma containing amyloid beta (Aβ) to enter the brain where the Aβ adheres preferentially to the surface of astrocytes.[56] These findings have led to the hypotheses that (1) breakdown of the blood–brain barrier allows access of neuron-binding autoantibodies and soluble exogenous Aβ42 to brain neurons and (2) binding of these autoantibodies to neurons triggers and/or facilitates the internalization and accumulation of cell surface-bound Aβ42 in vulnerable neurons through their natural tendency to clear surface-bound autoantibodies via endocytosis. Eventually the astrocyte is overwhelmed, dies, ruptures, and disintegrates, leaving behind the insoluble Aβ42 plaque. Thus, in some patients, Alzheimer's disease may be caused (or more likely, aggravated) by a breakdown in the blood–brain barrier.[57]
Cerebral edema[edit]
Cerebral edema is the accumulation of excess water in the extracellular space of the brain, which can result when hypoxia causes the blood–brain barrier to open.
Prion and prion-like diseases[edit]
Many neurodegenerative diseases including synucleinopathies such as Parkinson's, and tauopathies such as Alzheimer's are thought to result from seeded misfolding from pathological extracellular protein variants known as prions. This prion-like hypothesis is gaining support in numerous studies in vitro and involving in vivo intracerebral injection of brain lysates, extracted protein (tau, alpha-synuclein) and synthetically generated fibers in alpha-synucleinopathies. These proteins are also detectable in increasing amounts in the plasma of patients suffering from these conditions (particularly total alpha-synuclein in Parkinson's disease patients). The extent to which and the mechanisms by which these prion-like proteins can penetrate the blood–brain barrier is currently unknown.
HIV encephalitis[edit]
It is believed[58] that latent HIV can cross the blood–brain barrier inside circulating monocytes in the bloodstream ("Trojan horse theory") within the first 14 days of infection. Once inside, these monocytes become activated and are transformed into macrophages. Activated macrophages release virions into the brain tissue proximate to brain microvessels. These viral particles likely attract the attention of sentinel brain microglia and perivascular macrophages initiating an inflammatory cascade that may cause a series of intracellular signaling in brain microvascular endothelial cells and damage the functional and structural integrity of the BBB.[59] This inflammation is HIV encephalitis (HIVE). Instances of HIVE probably occur throughout the course of AIDS and are a precursor for HIV-associated dementia (HAD). The premier model for studying HIV and HIVE is the simian model.
Rabies[edit]
During lethal rabies infection of mice, the blood–brain barrier (BBB) does not allow anti-viral immune cells to enter the brain, the primary site of rabies virus replication. This aspect contributes to the pathogenicity of the virus and artificially increasing BBB permeability promotes viral clearance. Opening the BBB during rabies infection has been suggested as a possible novel approach to treating the disease, even though no attempts have yet been made to determine whether or not this treatment could be successful.[original research?]
Systemic inflammation[edit]
Inflammation in the body may lead to effects on the brain via the blood-brain barrier (BBB). During systemic inflammation, whether in the form of infection or sterile inflammation, the BBB may undergo changes which may be disruptive or non-disruptive.[60] Such changes may be part of a productive host response to systemic inflammation, or may lead to deleterious consequences within the central nervous system. These BBB changes likely play a role in the generation of sickness behaviour during systemic infection.[citation needed] These changes may also induce or accelerate disease within the brain, for example in multiple sclerosis and Alzheimer's disease, and may be part of the reason why patients with these conditions can deteriorate during an infection.[61][62] Also, in patients with neurological disease the BBB may be abnormally sensitive to the effects of systemic inflammation.
History[edit]
Paul Ehrlich was a bacteriologist studying staining, a procedure that is used in many microscopy studies to make fine biological structures visible using chemical dyes.[63] As Ehrlich injected some of these dyes (notably the aniline dyes that were then widely used), the dye stained all of the organs of some kinds of animals except for their brains.[63] At that time, Ehrlich attributed this lack of staining to the brain simply not picking up as much of the dye.[64]
However, in a later experiment in 1913, Edwin Goldmann (one of Ehrlich's students) injected the dye directly into the cerebrospinal fluids of animal brains. He found then the brains did become dyed, but the rest of the body did not, demonstrating the existence of a compartmentalization between the two. At that time, it was thought that the blood vessels themselves were responsible for the barrier, since no obvious membrane could be found. The concept of the blood–brain barrier (then termed hematoencephalic barrier) was proposed by a Berlin physician, Lewandowsky, in 1900.[65]
See also[edit]
Blood–air barrier
Blood–ocular barrier
Blood–retinal barrier
Blood–testis barrier
Blood–thymus barrier
Choroid plexus for blood–cerebrospinal fluid barrier
Ventricular system
Capillaries
Mast cell
Mobile phone radiation and health
Endothelium
Glymphatic system
Lina Stern
References[edit]
^ Jump up to: a b c d e f g Daneman, R; Prat, A (2015). "The Blood–Brain Barrier". Cold Spring Harbor Perspectives in Biology. 7 (1): a020412. doi:10.1101/cshperspect.a020412. PMC 4292164  . PMID 25561720.
Jump up ^ Johansen, A; Hansen, HD; Svarer, C; Szabolcs, L; Leth-Petersen, S; Kristensen, JL; Gillings, N; Knudsen, GM (2017). "The importance of small polar radiometabolites in molecular neuroimaging: A PET study with [11C]Cimbi-36 labeled in two positions". Journal of Cerebral Blood Flow and Metabolism. Epub (4): 659. doi:10.1177/0271678x17746179.
^ Jump up to: a b c Stamatovic, Svetlana M.; Keep, Richard F.; Andjelkovic, Anuska V. (2008). "Brain Endothelial Cell-Cell Junctions: How to 'Open' the Blood Brain Barrier". Current Neuropharmacology. 6 (3): 179–92. doi:10.2174/157015908785777210. PMC 2687937  . PMID 19506719 – via PubMed Central.
Jump up ^ Ballabh, Praveen; Braun, Alex; Nedergaard, Maiken (2004). "The blood–brain barrier: an overview: Structure, regulation, and clinical implications". Neurobiology of Disease. 16 (1): 1–13. doi:10.1016/j.nbd.2003.12.016. PMID 15207256.
Jump up ^ Leeuwen, Lisanne Martine van; Evans, Robert J.; Jim, Kin Ki; Verboom, Theo; Fang, Xiaoming; Bojarczuk, Aleksandra; Malicki, Jarema; Johnston, Simon Andrew; Sar, Astrid Marijke van der (2018-02-15). "A transgenic zebrafish model for the in vivo study of the blood and choroid plexus brain barriers using claudin 5". Biology Open. 7 (2): bio030494. doi:10.1242/bio.030494. ISSN 2046-6390. PMID 29437557.
Jump up ^ Abbott, N. Joan; Rönnbäck, Lars; Hansson, Elisabeth (2006). "Astrocyte–endothelial interactions at the blood–brain barrier". Nature Reviews Neuroscience. 7 (1): 41–53. doi:10.1038/nrn1824. PMID 16371949. (Subscription required (help)).
Jump up ^ Hamilton, R. D.; Foss, A. J.; Leach, L. (2007). "Establishment of a humanin vitromodel of the outer blood-retinal barrier". Journal of Anatomy. 211 (6): 707–16. doi:10.1111/j.1469-7580.2007.00812.x. PMC 2375847  . PMID 17922819 – via Wiley Online Library.
Jump up ^ Pritchard, Thomas C.; Alloway, Kevin Douglas (1999). Medical Neuroscience (Preview). Hayes Barton Press. pp. 76–7. ISBN 1-889325-29-5. OCLC 41086829. Retrieved 2009-02-08 – via Google Books.
Jump up ^ Gilgun-Sherki, Yossi; Melamed, Eldad; Offen, Daniel (2001). "Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier". Neuropharmacology. 40 (8): 959–75. doi:10.1016/S0028-3908(01)00019-3. PMID 11406187 – via Elsevier ScienceDirect. (Subscription required (help)).
Jump up ^ Tsai, Catherine E.; Daood, Monica J.; Lane, Robert H.; Hansen, Thor W.R.; Gruetzmacher, Elisa M.; Watchko, Jon F. (2002). "P-Glycoprotein Expression in Mouse Brain Increases with Maturation". Neonatology. 81 (1): 58–64. doi:10.1159/000047185. PMID 11803178.
^ Jump up to: a b Braun, Leon D.; Cornford, Eain M.; Oldendorf, William H. (1980). "Newborn Rabbit Blood–Brain Barrier Is Selectively Permeable and Differs Substantially from the Adult". Journal of Neurochemistry. 34 (1): 147–52. doi:10.1111/j.1471-4159.1980.tb04633.x. PMID 7452231.
^ Jump up to: a b c d Raza, Muhammad W.; Shad, Amjad; Pedler, Steve J; Karamat, Karamat A. (2005). "Penetration and activity of antibiotics in brain abscess". Journal of the College of Physicians and Surgeons Pakistan. 15 (3): 165–7. PMID 15808097.
Jump up ^ Pardridge, William M (2011). "Drug transport in brain via the cerebrospinal fluid". Fluids Barriers CNS. 8 (1): 7. doi:10.1186/2045-8118-8-7. PMC 3042981  . PMID 21349155.
Jump up ^ Chen, Y (2013). "Novel modified method for injection into the cerebrospinal fluid via the cerebellomedullary cistern in mice". Acta Neurobiologiae Experimentalis. 73 (2): 304–11. PMID 23823990.
Jump up ^ Tortora, Gerard J.; Berdell R. Funke; Christine L. Case (2010). Microbiology: An Introduction. San Francisco: Benjamin Cummings. p. 439,611. ISBN 0-321-55007-2.
Jump up ^ Nizet, V; KS, Kim; M, Stins; M, Jonas; EY, Chi; D, Nguyen; CE, Rubens (1997). "Invasion of brain microvascular endothelial cells by group B streptococci". Infection and Immunity. 65 (12): 5074–5081. PMC 175731  . PMID 9393798.
Jump up ^ Zysk, Gregor (2001). "Pneumolysin Is the Main Inducer of Cytotoxicity to Brain Microvascular Endothelial Cells Caused by Streptococcus pneumoniae". Infection and Immunity. 69 (2): 845–852. doi:10.1128/IAI.69.2.845-852.2001. PMC 97961  . PMID 11159977.
Jump up ^ Van Sorge, Nina M (2012). "Defense at the border: the blood–brain barrier versus bacterial foreigners". Future Microbiol. 7 (3): 383–394. doi:10.2217/fmb.12.1. PMC 3589978  . PMID 22393891.
^ Jump up to: a b c d Gross PM, Weindl A (1987). "Peering through the windows of the brain (Review)". Journal of Cerebral Blood Flow and Metabolism. 7 (6): 663–72. doi:10.1038/jcbfm.1987.120. PMID 2891718. CS1 maint: Uses authors parameter (link)
^ Jump up to: a b Gross, P. M (1992). "Circumventricular organ capillaries". Progress in Brain Research. 91: 219–33. PMID 1410407.
^ Jump up to: a b Miyata, S (2015). "New aspects in fenestrated capillary and tissue dynamics in the sensory circumventricular organs of adult brains". Frontiers in Neuroscience. 9: 390. doi:10.3389/fnins.2015.00390. PMC 4621430  . PMID 26578857.
^ Jump up to: a b c d Rodríguez Esteban M.; Blázquez Juan L.; Guerra Montserrat (2010). "The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: The former opens to the portal blood and the latter to the cerebrospinal fluid". Peptides. 31 (4): 757–76. doi:10.1016/j.peptides.2010.01.003. PMID 20093161.
^ Jump up to: a b Gross, PM; Wall, KM; Pang, JJ; Shaver, SW; Wainman, DS (1990). "Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 259 (6 Pt 2): R1131–8. doi:10.1152/ajpregu.1990.259.6.R1131. PMID 2260724.
^ Jump up to: a b Shaver, SW; Pang, JJ; Wainman, DS; Wall, KM; Gross, PM (1992). "Morphology and function of capillary networks in subregions of the rat tuber cinereum". Cell and Tissue Research. 267 (3): 437–48. PMID 1571958.
Jump up ^ Marcos-Contreras, O. A.; Martinez de Lizarrondo, S.; Bardou, I.; Orset, C.; Pruvost, M.; Anfray, A.; Frigout, Y.; Hommet, Y.; Lebouvier, L.; Montaner, J.; Vivien, D.; Gauberti, M. (2016). "Hyperfibrinolysis increases blood brain barrier permeability by a plasmin and bradykinin-dependent mechanism". Blood. 128 (20): 2423–2434. doi:10.1182/blood-2016-03-705384. PMID 27531677.
Jump up ^ McDannold, Nathan; Vykhodtseva, Natalia; Hynynen, Kullervo (May 2008). "Blood–brain barrier disruption induced by focused ultrasound and circulating preformed microbubbles appears to be characterized by the mechanical index". Ultrasound in Medicine and Biology. Elsevier. 34 (5): 834–840. doi:10.1016/j.ultrasmedbio.2007.10.016. PMC 2442477  . PMID 18207311.
Jump up ^ Wiley, Devin (2013). "Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor". Proc Natl Acad Sci U S A. 110 (21): 8662–7. Bibcode:2013PNAS..110.8662W. doi:10.1073/pnas.1307152110. PMC 3666717  . PMID 23650374.
Jump up ^ Paris-Robidas S, Emond V, Tremblay C, Soulet D, Calon F (July 2011). "In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor". Molecular Pharmacology. 80 (1): 32–9. doi:10.1124/mol.111.071027. PMID 21454448.
Jump up ^ Krol, Silke; MacRez, Richard; Docagne, Fabian; Defer, Gilles; Laurent, Sophie; Rahman, Masoud; Hajipour, Mohammad J.; Kehoe, Patrick G.; Mahmoudi, Morteza (2013). "Therapeutic Benefits from Nanoparticles: The Potential Significance of Nanoscience in Diseases with Compromise to the Blood Brain Barrier". Chemical Reviews. 113 (3): 1877–1903. doi:10.1021/cr200472g. PMID 23157552 – via ACS Publications. (Subscription required (help)).
Jump up ^ Silva, GA (December 2008). "Nanotechnology approaches to crossing the blood–brain barrier and drug delivery to the CNS". BMC Neuroscience. 9: S4. doi:10.1186/1471-2202-9-S3-S4. PMC 2604882  . PMID 19091001 – via BioMed Central.
Jump up ^ Brigger, I.; Morizet, J; Aubert, G; Chacun, H; Terrier-Lacombe, MJ; Couvreur, P; Vassal, G (December 2002). "Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting". Journal of Pharmacology and Experimental Therapeutics. 303 (3): 928–36. doi:10.1124/jpet.102.039669. PMID 12438511 – via ASPET.
Jump up ^ Kreuter, Jörg (2014). "Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?". Advanced Drug Delivery Reviews. 71: 2–14. doi:10.1016/j.addr.2013.08.008. PMID 23981489 – via Elsevier ScienceDirect. (Subscription required (help)).
Jump up ^ Nair, Madhavan; Guduru, Rakesh; Liang, Ping; Hong, Jeongmin; Sagar, Vidya; Khizroev, Sakhrat (2013). "Externally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriers". Nature Communications. 4: 1707. Bibcode:2013NatCo...4E1707N. doi:10.1038/ncomms2717. PMID 23591874.
Jump up ^ Hashizume, Hiroya; Baluk, Peter; Morikawa, Shunichi; McLean, John W.; Thurston, Gavin; Roberge, Sylvie; Jain, Rakesh K.; McDonald, Donald M. (April 2000). "Openings between Defective Endothelial Cells Explain Tumor Vessel Leakiness". American Journal of Pathology. 156 (4): 1363–80. doi:10.1016/S0002-9440(10)65006-7. PMC 1876882  . PMID 10751361.
Jump up ^ Schneider, Stefan W.; Ludwig, Thomas; Tatenhorst, Lars; Braune, Stephan; Oberleithner, Hans; Senner, Volker; Paulus, Werner (March 2004). "Glioblastoma cells release factors that disrupt blood–brain barrier features". Acta Neuropathologica. 107 (3): 272–6. doi:10.1007/s00401-003-0810-2. PMID 14730455 – via SpringerLink. (Subscription required (help)).
Jump up ^ Van Dorpe, Sylvia; Bronselaer, Antoon; Nielandt, Joachim; Stalmans, Sofie; Wynendaele, Evelien; Audenaert, Kurt; Van De Wiele, Christophe; Burvenich, Christian; Peremans, Kathelijne; Hsuchou, Hung; De Tré, Guy; De Spiegeleer, Bart (2012). "Brainpeps: the blood–brain barrier peptide database". Brain Structure and Function. 217 (3): 687–718. doi:10.1007/s00429-011-0375-0. PMID 22205159 – via SpringerLink. (Subscription required (help)).
Jump up ^ "Transport at the Blood Brain Barrier (BBB)". The Davis Lab. The University of Arizona. Retrieved 2015-01-05.
Jump up ^ Ermisch, A.; Ruhle, H.-J.; Neubert, K.; Hartrodt, B.; Landgraf, R. (1983). "On the Blood-Brain Barrier to Peptides: [3H]βCasomorphin-5 Uptake by Eighteen Brain Regions In Vivo". Journal of Neurochemistry. 41 (5): 1229–33. doi:10.1111/j.1471-4159.1983.tb00816.x. PMID 6619862 – via Wiley Online Library. (Subscription required (help)).
Jump up ^ Beam, T. R.; Allen, J. C. (December 1977). "Blood, Brain, and Cerebrospinal Fluid Concentrations of Several Antibiotics in Rabbits with Intact and Inflamed Meninges". Antimicrobial Agents and Chemotherapy. 12 (6): 710–6. doi:10.1128/AAC.12.6.710. PMC 430009  . PMID 931369.
Jump up ^ Tortora, Gerard J.; Berdell R. Funke; Christine L. Case (2010). Microbiology: An Introduction. San Francisco: Benjamin Cummings. p. 615. ISBN 0-321-55007-2.
Jump up ^ Nordqvist, Christian (2010-04-16). "What Is A Brain Abscess (Cerebral Abscess)?". MNT Knowledge Center. Medical News Today. Archived from the original on 2010-04-18.
Jump up ^ Oby, Emily; Janigro, Damir (2006). "The Blood–Brain Barrier and Epilepsy". Epilepsia. 47 (11): 1761–1774. doi:10.1111/j.1528-1167.2006.00817.x. ISSN 0013-9580. PMID 17116015.
Jump up ^ Marchi, Nicola; Angelov, Lilyana; Masaryk, Thomas; Fazio, Vincent; Granata, Tiziana; Hernandez, Nadia; Hallene, Kerri; Diglaw, Tammy; Franic, Linda; Najm, Imad; Janigro, Damir (2007). "Seizure-Promoting Effect of Blood?Brain Barrier Disruption". Epilepsia. 48 (4): 732–42. doi:10.1111/j.1528-1167.2007.00988.x. PMC 4135474  . PMID 17319915.
Jump up ^ Seiffert, E.; Dreier, JP; Ivens, S; Bechmann, I; Tomkins, O; Heinemann, U; Friedman, A (2004). "Lasting Blood-Brain Barrier Disruption Induces Epileptic Focus in the Rat Somatosensory Cortex". Journal of Neuroscience. 24 (36): 7829–36. doi:10.1523/JNEUROSCI.1751-04.2004. PMID 15356194.
Jump up ^ Uva, L.; Librizzi, L.; Marchi, N.; Noe, F.; Bongiovanni, R.; Vezzani, A.; Janigro, D.; De Curtis, M. (2008). "Acute induction of epileptiform discharges by pilocarpine in the in vitro isolated guinea-pig brain requires enhancement of blood–brain barrier permeability". Neuroscience. 151 (1): 303–12. doi:10.1016/j.neuroscience.2007.10.037. PMC 2774816  . PMID 18082973.
Jump up ^ Van Vliet, E. A.; Da Costa Araujo, S.; Redeker, S.; Van Schaik, R.; Aronica, E.; Gorter, J. A. (2007). "Blood–brain barrier leakage may lead to progression of temporal lobe epilepsy". Brain. 130 (2): 521–534. doi:10.1093/brain/awl318. PMID 17124188.
Jump up ^ Ivens, S.; Kaufer, D.; Flores, L. P; Bechmann, I.; Zumsteg, D.; Tomkins, O.; Seiffert, E.; Heinemann, U.; Friedman, A. (2007). "TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis". Brain. 130 (Pt 2): 535–47. doi:10.1093/brain/awl317. PMID 17121744.
Jump up ^ Awasthi, Sanjay; Hallene, Kerri L; Fazio, Vince; Singhal, Sharad S; Cucullo, Luca; Awasthi, Yogesh C; Dini, Gabriele; Janigro, Damir (2005). "RLIP76, a non-ABC transporter, and drug resistance in epilepsy". BMC Neuroscience. 6: 61. doi:10.1186/1471-2202-6-61. PMC 1249579  . PMID 16188027.
Jump up ^ Löscher, Wolfgang; Potschka, Heidrun (2005). "Drug resistance in brain diseases and the role of drug efflux transporters". Nature Reviews Neuroscience. 6 (8): 591–602. doi:10.1038/nrn1728. PMID 16025095.
Jump up ^ Waubant, Emmanuelle (2006). "Biomarkers indicative of blood–brain barrier disruption in multiple sclerosis". Disease Markers. 22 (4): 235–44. doi:10.1155/2006/709869. PMC 3850823  . PMID 17124345.
Jump up ^ Schinkel AH (April 1999). "P-Glycoprotein, a gatekeeper in the blood–brain barrier". Advanced Drug Delivery Reviews. 36 (2–3): 179–194. doi:10.1016/S0169-409X(98)00085-4. PMID 10837715.
Jump up ^ Schreibelt, G; Musters, RJ; Reijerkerk, A; De Groot, LR; Van Der Pol, SM; Hendrikx, EM; Döpp, ED; Dijkstra, CD; Drukarch, B; De Vries, HE (August 2006). "Lipoic acid affects cellular migration into the central nervous system and stabilizes blood–brain barrier integrity". J. Immunol. 177 (4): 2630–7. doi:10.4049/jimmunol.177.4.2630. PMID 16888025.
Jump up ^ Lennon, V. A.; Kryzer, TJ; Pittock, SJ; Verkman, AS; Hinson, SR (August 2005). "IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel". J. Exp. Med. 202 (4): 473–7. doi:10.1084/jem.20050304. PMC 2212860  . PMID 16087714.
Jump up ^ Pascual, J.; Wang, D; Lecumberri, B; Yang, H; Mao, X; Yang, R; De Vivo, DC (May 2004). "GLUT1 deficiency and other glucose transporter diseases". European Journal of Endocrinology. 150 (5): 627–33. doi:10.1530/eje.0.1500627. PMID 15132717.
Jump up ^ Klepper, Jörg; Voit, Thomas (June 2002). "Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain—a review". European journal of pediatrics. 161 (6): 295–304. doi:10.1007/s00431-002-0939-3. PMID 12029447.
Jump up ^ Zipser, BD; Johanson, CE; Gonzalez, L; Berzin, TM; Tavares, R; Hulette, CM; Vitek, MP; Hovanesian, V; Stopa, EG (2007). "Microvascular injury and blood–brain barrier leakage in Alzheimer's disease". Neurobiology of Aging. 28 (7): 977–86. doi:10.1016/j.neurobiolaging.2006.05.016. PMID 16782234. (Subscription required (help)).
Jump up ^ Nagele, Robert G. (2006). "Alzheimer's disease: new mechanisms for an old problem". UMDNJ Research. University of Medicine and Dentistry of New Jersey. 7 (2). Archived from the original on 2011-09-17. Retrieved 2011-07-22.
Jump up ^ Williams, Kenneth C.; Hickey, William F. (2002). "Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS". Annual Review of Neuroscience. 25: 537–62. doi:10.1146/annurev.neuro.25.112701.142822. PMID 12052920.
Jump up ^ Ivey, Nathan S; MacLean, Andrew G; Lackner, Andrew A (2009). "Acquired immunodeficiency syndrome and the blood-brain barrier". Journal of Neurovirology. 15 (2): 111–22. doi:10.1080/13550280902769764. PMC 2744422  . PMID 19306229.
Jump up ^ Varatharaj, Aravinthan; Galea, Ian (2016). "The blood-brain barrier in systemic inflammation". Brain, Behavior, and Immunity. 60: 1–12. doi:10.1016/j.bbi.2016.03.010. PMID 26995317.
Jump up ^ Ortiz, GG; Pacheco-Moisés, FP; Macías-Islas, MÁ; Flores-Alvarado, LJ; Mireles-Ramírez, MA; González-Renovato, ED; Hernández-Navarro, VE; Sánchez-López, AL; Alatorre-Jiménez, MA (November 2014). "Role of the blood-brain barrier in multiple sclerosis". Archives of medical research. 45 (8): 687–97. doi:10.1016/j.arcmed.2014.11.013. PMID 25431839.
Jump up ^ Erickson, MA; Banks, WA (October 2013). "Blood-brain barrier dysfunction as a cause and consequence of Alzheimer's disease". Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. 33 (10): 1500–13. doi:10.1038/jcbfm.2013.135. PMC 3790938  . PMID 23921899.
^ Jump up to: a b Saunders, N. R; Dziegielewska, K. M; Møllgård, K; Habgood, M. D (2015). "Markers for blood-brain barrier integrity: How appropriate is Evans blue in the twenty-first century and what are the alternatives?". Frontiers in Neuroscience. 9: 385. doi:10.3389/fnins.2015.00385. PMC 4624851  . PMID 26578854.
Jump up ^ "History of Blood-Brain Barrier". Davis Lab. Retrieved 5 January 2015.
Jump up ^ "History of Blood-Brain Barrier". The Davis Lab. University of Arizona. Archived from the original on 2012-04-25. Retrieved 2014-03-01.
Further reading[edit]
Interlandi, Jeneen (2013). ""Messing With" the Blood-Brain Barrier May Be Key to Treating a Host of Diseases". Scientific American. 2013 (June). Retrieved 6 June 2013. (subscription required)
Shityakov, S., Salvador, E., Förster, C. In silico, in vitro, and in vivo methods to analyse drug permeation across the blood–brain barrier: A critical review. OA Anaesthetics 2013, 1(2):13. [1]
Derricott, Caitlin (2015). "Using water–solvent systems to estimate in vivo blood–tissue partition coefficients". Chemistry Central. 9 (58). Retrieved 16 October 2015.
External links[edit]
Media related to Blood–brain barrier at Wikimedia Commons
[hide]
v
t
e
Ventricular system of the human brain
Lateral ventricles
Body
Lamina affixa
Stria terminalis
Collateral eminence
Occipital horn
Calcar avis
Septum pellucidum
Third ventricle
Recesses
Optic recess
Infundibular recess
Suprapineal recess
Pineal recess
Hypothalamic sulcus
Tela choroidea
Subfornical organ
Posterior commissure
Fourth ventricle
Roof
Superior medullary velum
Frenulum
Inferior medullary velum
Taenia
Floor
Upper
Facial colliculus
Locus coeruleus
Lower
Vagal trigone
Hypoglossal trigone
Area postrema
Obex
Medial eminence
Sulcus limitans
Fastigium
Apertures
Median/Magendie
Lateral recess to Lateral/Luschka
Other
Rhomboid fossa
Tela choroidea
Cerebrospinal fluid
Blood–brain barrier
Cerebral aqueduct
Interventricular foramina
Perilymphatic duct
Authority control
GND: 4007279-4
NDL: 00575620
Retrieved from "https://en.wikipedia.org/w/index.php?title=Blood–brain_barrier&oldid=842590052"
Categories:
Central nervous system
Neurology
Animal physiology
Pharmacokinetics
Brain
Circulatory system
Hidden categories:
Pages with unresolved properties
Pages containing links to subscription-only content
CS1 maint: Uses authors parameter
All articles that may contain original research
Articles that may contain original research from March 2013
All articles with unsourced statements
Articles with unsourced statements from April 2018
Commons category with page title different than on Wikidata
Wikipedia articles with GND identifiers
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Article
Talk
Variants
Views
Read
Edit
View history
More
Search
Navigation
Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store
Interaction
Help
About Wikipedia
Community portal
Recent changes
Contact page
Tools
What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Wikidata item
Cite this page
Print/export
Create a book
Download as PDF
Printable version
In other projects
Wikimedia Commons
Languages
العربية
Беларуская
Български
Català
Čeština
Dansk
Deutsch
Eesti
Ελληνικά
Español
Euskara
فارسی
Français
Gaeilge
Galego
한국어
Հայերեն
Bahasa Indonesia
Íslenska
Italiano
עברית
Nederlands
日本語
Norsk
Norsk nynorsk
Polski
Português
Română
Русский
Simple English
Slovenčina
Slovenščina
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi
Svenska
Türkçe
Українська
Tiếng Việt
中文
31 more
Edit links
This page was last edited on 23 May 2018, at 12:16.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Developers
Cookie statement
Mobile view
Enable previews

key: html

type: local

value: div

attrs: id class

values: mw-page-base noprint

values: mw-head-base noprint

value: a

attrs: id class lang

values: firstHeading firstHeading en

values: siteSub noprint

values: jump-to-nav mw-jump

value: i

attrs: colspan style

attrs: href class

attrs: href title

attrs: scope style

values:
/wiki/Circumventricular_organ
mw-redirect
Circumventricular organ

attrs: alt src width height class srcset data-file-width data-file-height

values:
/wiki/Tight_junctions
mw-redirect
Tight junctions

values:
/wiki/Endothelial_cell
mw-redirect
Endothelial cell

values:
/wiki/Junctional_adhesion_molecule
mw-redirect
Junctional adhesion molecule

values:
/wiki/Amino_acids
mw-redirect
Amino acids

values:
/wiki/Neurological_disease
mw-redirect
Neurological disease

values: Edit section: Specialized permeable zones

values:
/wiki/Nucleus_tractus_solitarii
mw-redirect
Nucleus tractus solitarii

values: Nanoparticles for drug delivery to the brain

values:
/wiki/Auto-immune_disorder
mw-redirect
Auto-immune disorder

values:
/wiki/Neurodegenerative_disorder
mw-redirect
Neurodegenerative disorder

values:
/wiki/Insulation_(electrical)
mw-redirect
Insulation (electrical)

values:
/wiki/T_lymphocytes
mw-redirect
T lymphocytes

values: Edit section: Late-stage neurological trypanosomiasis (sleeping sickness)

values: Edit section: Progressive multifocal leukoencephalopathy (PML)

values:
/wiki/JC_polyomavirus
mw-redirect
JC polyomavirus

values:
/wiki/De_Vivo_disease
mw-redirect
De Vivo disease

values: Edit section: Prion and prion-like diseases

values:
/wiki/Trojan_horse
mw-redirect
Trojan horse

values:
/wiki/HIV-associated_dementia
mw-redirect
HIV-associated dementia

values: The material near this tag possibly contains original research. (March 2013)

values: This claim needs references to reliable sources. (April 2018)

values:
noprint Inline-Template Template-Fact
white-space:nowrap;

values:
/wiki/Aniline_dye
mw-redirect
Aniline dye

values:
nofollow
external text
//doi.org/10.1101%2Fcshperspect.a020412

attrs: alt src title width height srcset data-file-width data-file-height

values:
/wiki/PubMed_Identifier
mw-redirect
PubMed Identifier

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25561720

values:
nofollow
external text
//doi.org/10.1177%2F0271678x17746179

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19506719

values:
nofollow
external text
//doi.org/10.1016%2Fj.nbd.2003.12.016

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15207256

values:
nofollow
external text
//doi.org/10.1242%2Fbio.030494

values:
nofollow
external text
//www.worldcat.org/issn/2046-6390

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/29437557

values:
/wiki/Nat._Rev._Neurosci.
mw-redirect
Nat. Rev. Neurosci.

values:
nofollow
external text
//doi.org/10.1038%2Fnrn1824

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16371949

values: The site requires a paid subscription to access this page.

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17922819

values:
nofollow
external text
//www.worldcat.org/oclc/41086829

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11406187

values:
nofollow
external text
//doi.org/10.1159%2F000047185

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11803178

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/7452231

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15808097

values:
nofollow
external text
//doi.org/10.1186%2F2045-8118-8-7

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21349155

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23823990

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/9393798

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/11159977

values:
nofollow
external text
//doi.org/10.2217%2Ffmb.12.1

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22393891

values:
nofollow
external text
//doi.org/10.1038%2Fjcbfm.1987.120

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2891718

values: Category:CS1 maint: Uses authors parameter

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1410407

values:
nofollow
external text
//doi.org/10.3389%2Ffnins.2015.00390

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26578857

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20093161

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/2260724

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1571958

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27531677

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18207311

values:
nofollow
external text
//doi.org/10.1073%2Fpnas.1307152110

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23650374

values:
nofollow
external text
//doi.org/10.1124%2Fmol.111.071027

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21454448

values:
nofollow
external text
//doi.org/10.1021%2Fcr200472g

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23157552

values:
/wiki/BMC_Neurosci.
mw-redirect
BMC Neurosci.

values:
nofollow
external text
//doi.org/10.1186%2F1471-2202-9-S3-S4

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19091001

values:
/wiki/J._Pharmacol._Exp._Ther.
mw-redirect
J. Pharmacol. Exp. Ther.

values:
nofollow
external text
//doi.org/10.1124%2Fjpet.102.039669

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12438511

values:
/wiki/Adv._Drug_Deliv._Rev.
mw-redirect
Adv. Drug Deliv. Rev.

values:
nofollow
external text
//doi.org/10.1016%2Fj.addr.2013.08.008

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23981489

values:
/wiki/Nat._Commun.
mw-redirect
Nat. Commun.

values:
nofollow
external text
//doi.org/10.1038%2Fncomms2717

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23591874

values:
/wiki/Am._J._Pathol.
mw-redirect
Am. J. Pathol.

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10751361

values:
/wiki/Acta_Neuropathol._(Berl)
mw-redirect
Acta Neuropathol. (Berl)

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/14730455

values:
/wiki/Brain_Struct._Func.
mw-redirect
Brain Struct. Func.

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22205159

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/6619862

values:
nofollow
external text
//doi.org/10.1128%2FAAC.12.6.710

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/931369

values:
nofollow
external text
//www.worldcat.org/issn/0013-9580

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17116015

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17319915

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15356194

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/18082973

values:
nofollow
external text
//doi.org/10.1093%2Fbrain%2Fawl318

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17124188

values:
nofollow
external text
//doi.org/10.1093%2Fbrain%2Fawl317

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17121744

values:
nofollow
external text
//doi.org/10.1186%2F1471-2202-6-61

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16188027

values:
nofollow
external text
//doi.org/10.1038%2Fnrn1728

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16025095

values:
nofollow
external text
//doi.org/10.1155%2F2006%2F709869

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17124345

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/10837715

values:
nofollow
external text
//doi.org/10.4049%2Fjimmunol.177.4.2630

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16888025

values:
nofollow
external text
//doi.org/10.1084%2Fjem.20050304

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16087714

values:
nofollow
external text
//doi.org/10.1530%2Feje.0.1500627

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/15132717

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12029447

values:
/wiki/Neurobiol._Aging
mw-redirect
Neurobiol. Aging

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16782234

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/12052920

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/19306229

values:
nofollow
external text
//doi.org/10.1016%2Fj.bbi.2016.03.010

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26995317

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/25431839

values:
nofollow
external text
//doi.org/10.1038%2Fjcbfm.2013.135

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/23921899

values:
nofollow
external text
//doi.org/10.3389%2Ffnins.2015.00385

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26578854

values: -moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;

values:
/wiki/Pineal_recess
mw-redirect
Pineal recess

values:
/wiki/Tela_choroidea_of_third_ventricle
mw-redirect
Tela choroidea of third ventricle

values: Medial eminence of floor of fourth ventricle

values:
/wiki/Fastigium_of_fourth_ventricle
mw-redirect
Fastigium of fourth ventricle

values: nowraplinks collapsible autocollapse navbox-inner

values:
nofollow
external text
https://d-nb.info/gnd/4007279-4

values: Category:Pages with unresolved properties

values: Category:Pages containing links to subscription-only content

values: Category:All articles that may contain original research

values: Category:Articles that may contain original research from March 2013

values: Category:All articles with unsourced statements

values: Category:Articles with unsourced statements from April 2018

values: Category:Commons category with page title different than on Wikidata

values: Category:Wikipedia articles with GND identifiers

values: Discussion about edits from this IP address [ctrl-alt-n]

values: A list of edits made from this IP address [ctrl-alt-y]

values: You are encouraged to create an account and log in; however, it is not mandatory

values: You're encouraged to log in; however, it's not mandatory. [ctrl-alt-o]

values:
/wiki/Blood%E2%80%93brain_barrier
View the content page [ctrl-alt-c]
c

values: Discussion about the content page [ctrl-alt-t]

values: p-namespaces navigation vectorTabs p-namespaces-label

values:
p-variants
navigation
vectorMenu emptyPortlet
p-variants-label

values: Past revisions of this page [ctrl-alt-h]

values: p-views navigation vectorTabs p-views-label

values:
p-cactions
navigation
vectorMenu emptyPortlet
p-cactions-label

values:
mw-wiki-logo
/wiki/Main_Page
Visit the main page

values:
/wiki/Main_Page
Visit the main page [ctrl-alt-z]
z

values: Featured content – the best of Wikipedia

values: Find background information on current events

values:
/wiki/Special:Random
Load a random article [ctrl-alt-x]
x

values: portal navigation p-navigation p-navigation-label

values: Guidance on how to use and edit Wikipedia

values: About the project, what you can do, where to find things

values: A list of recent changes in the wiki [ctrl-alt-r]

values: portal navigation p-interaction p-interaction-label

values: List of all English Wikipedia pages containing links to this page [ctrl-alt-j]

values: حاجز دموي دماغي – Arabic

values: Гемата-энцэфалічны бар’ер – Belarusian

values:
interlanguage-link interwiki-be
display: none;

values: Кръвно-мозъчна бариера – Bulgarian

values:
interlanguage-link interwiki-bg
display: none;

values:
interlanguage-link interwiki-ca
display: none;

values:
interlanguage-link interwiki-cs
display: none;

values:
interlanguage-link interwiki-da
display: none;

values: interlanguage-link interwiki-de badge-Q17437796 badge-featuredarticle

values:
interlanguage-link interwiki-et
display: none;

values: Αιματοεγκεφαλικός φραγμός – Greek

values:
interlanguage-link interwiki-el
display: none;

values:
interlanguage-link interwiki-eu
display: none;

values: سد خونی مغزی – Persian

values:
interlanguage-link interwiki-fa
display: none;

values:
interlanguage-link interwiki-ga
display: none;

values:
interlanguage-link interwiki-gl
display: none;

values: 혈액뇌장벽 – Korean

values:
interlanguage-link interwiki-ko
display: none;

values: Արյունաուղեղային պատնեշ – Armenian

values:
interlanguage-link interwiki-hy
display: none;

values:
interlanguage-link interwiki-is
display: none;

values:
interlanguage-link interwiki-it
display: none;

values: מחסום דם־מוח – Hebrew

values:
interlanguage-link interwiki-he
display: none;

values:
interlanguage-link interwiki-nl
display: none;

values:
interlanguage-link interwiki-no
display: none;

values: Blod-hjernebarrieren – Norwegian Nynorsk

values:
interlanguage-link interwiki-nn
display: none;

values:
interlanguage-link interwiki-pl
display: none;

values:
interlanguage-link interwiki-ro
display: none;

values: Гемато-энцефалический барьер – Russian

values: interlanguage-link interwiki-ru badge-Q17437796 badge-featuredarticle

values:
interlanguage-link interwiki-simple
display: none;

values:
interlanguage-link interwiki-sk
display: none;

values:
interlanguage-link interwiki-sl
display: none;

values:
interlanguage-link interwiki-sr
display: none;

values:
interlanguage-link interwiki-sh
display: none;

values:
interlanguage-link interwiki-fi
display: none;

values:
interlanguage-link interwiki-sv
display: none;

values:
interlanguage-link interwiki-tr
display: none;

values: Гематоенцефалічний бар'єр – Ukrainian

values:
interlanguage-link interwiki-uk
display: none;

values:
interlanguage-link interwiki-vi
display: none;

values: All languages (initial selection from common choices by you and others)

values: mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Blood–brain_barrier rootpage-Blood–brain_barrier skin-vector action-view